Palonosetoron+Aprepitant+Dexamethasone Therapy in patients receiving moderately emetogenic anticancer drugs (EJCG-1001)

Palonosetoron+Aprepitant+Dexamethasone Therapy in patients receiving moderately emetogenic anticancer drugs (EJCG-1001) - Palonosetoron+Aprepitant+Dexamethasone Therapy in patients receiving moderately emetogenic anticancer drugs (EJCG-1001)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006498

Enrollment

Registered

2011-10-07

Start date

2010-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

1)Aprepitant: 125mg po. 1-1.5 hr. prior to chemotherapy on Day1 80mg po. on Day 2-3. (2)Palonosetron 0.75mg iv. prior to chemotherapy on Day1 (3)Dexamethasone: 4.95mg iv. 30 min. prior to

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)No prior chemotherapy 2)Patient receiving in CBDCA and Histologically or cytologically proven Lung cancer 3)ECOG performance status of 0 to 2 4)>=Age 20 6) Ability to ingestion intake and drug administration orally 7)Written IC.

Exclusion criteria

Exclusion criteria: 1)Severe complications 2)Symptomatic brain meta 4) Massive pleural or abdominal effusion 5) Intestinal paralysis or ileus 7)Hypersensitivity for PaIonosetron, Aprepitant, Dexamethasone 9) Pregnant or lactating 10) Other patients who are unfit for the study as determined by the attending physician.

Design outcomes

Primary

Measure	Time frame
Complete response rate in chemotherapy of CBDCA	—

Countries

Japan

Contacts

Public ContactToshimichi Miya

Nippom Medical School Tamanagayama Hospital Department of Pulmonary Medicine

tmiya@nms.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026